Probiotics and methotrexate for early psoriasis
Treatments studied
Part of Skin clinical trials.
This pilot study tests whether adding probiotics to standard methotrexate treatment improves symptoms in people newly diagnosed with chronic plaque psoriasis. It aims to see how the gut microbiome affects treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with chronic plaque psoriasis (red, scaly patches on the skin).
- You have not used psoriasis medications that affect the whole body (like biologics or oral treatments) in the last 3 months, except for acitretin, which cannot have been used in the last 3 years.
- You do not have other skin diseases or autoimmune conditions (such as lupus, lichen planus, dermatomyositis, or vitiligo).
- You are not pregnant or breastfeeding.
- You have no conditions that make methotrexate unsafe (your doctor will check this).
- You are willing to take probiotics daily and report your progress over 16 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a specific gene change (called TRAF3IP2) in people with psoriasis or psoriatic arthritis who are about to start methotrexate. The goal is to see if the gene affects how well the treatment works or if it causes side effects.
This study compares two oral pill treatments—methotrexate and tofacitinib—for people with chronic plaque psoriasis that is moderate to severe and hasn't responded well to creams. The goal is to see which pill works better at clearing skin.
This study compares two medications, methotrexate and tofacitinib, to see which works better for chronic plaque psoriasis in adults with moderate to severe symptoms. If you've tried creams that didn't help enough, you may be eligible.
This trial tests two oral medications, Apremilast and Methotrexate, to see which works better for people with moderate to severe plaque psoriasis. You must not have taken systemic treatments (pills or shots that work throughout the body) in the last 3 months.
This trial tests if a treatment can prevent joint damage in people recently diagnosed with psoriatic arthritis. It compares a standard medication (methotrexate) with or without a newer biologic drug (adalimumab) to see which is better at stopping the disease from causing lasting harm.
This trial tests if methotrexate, a medication that calms the immune system, can help adults with moderate-to-severe eczema that hasn't improved with creams or other treatments. You'll either receive methotrexate or a placebo to see which works better.
Hear when a new Psoriasis (PsO) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.